Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications
Publication partner logo
Publication partner link
https://www.novartis.co.uk

Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target.

  • Read more about Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target.

Alam, M., Sanchez-Azqueta, A., Janha, O., Flannery, E., Mahindra, A., Mapesa, K., ... Tobin A. (2019). Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682.

The promise and peril of chemical probes.

  • Read more about The promise and peril of chemical probes.

Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., … Zuercher, W. J. (2015). The promise and peril of chemical probes. Nature chemical biology, 11(8), 536–541.

An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains

  • Read more about An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains

D'Ascenzio, M., Pugh, KM., Konietzny, R., Berridge, G., Tallant, C., Hashem, S., ... Brennan, PE. (2019). An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains. Angew Chemie International Edition, 58(4), 1007-1012.

Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3)

  • Read more about Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3)

Kaniskan, H. Ü., Eram, M. S., Zhao, K., Szewczyk, M. M., Yang, X., Schmidt, K., … Jin, J. (2018). Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3). Journal of Medicinal Chemistry, 61(3), 1204–1217.

Progress towards a public chemogenomic set for protein kinases and a call for contributions

  • Read more about Progress towards a public chemogenomic set for protein kinases and a call for contributions

Drewry, D. H., Wells, C. I., Andrews, D. M., Angell, R., Al-Ali, H., Axtman, A. D., … Willson, T. M. (2017). Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS ONE, 12(8), e0181585.

Subscribe to Novartis
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility